Skip to main content

Why the FDA didn’t grant an approval to Lilly’s Alzheimer’s drug

The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.